Daunorubicin
Information
- Drug Name
- Daunorubicin
- Description
- Entry(CIViC)
- 13
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Daunorubicin treatment resulted in similar overall... | DNMT3A | DNMT3A R882 DNMT3A R882 | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Ba/F3 cells with both FLT3-ITD and TKD mutations o... | FLT3 | FLT3 ITD FLT3 ITD | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| WT1 mutations were associated with an inferior res... | WT1 | WT1 EXON 7 MUTATION WT1 EXON 7 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Young patients (18-60) with NPM1 mutations had imp... | NPM1 | NPM1 EXON 12 MUTATION NPM1 EXON 12 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| SU11248 + Daunorubicin has a synergic effect on Mu... | FLT3 |
FLT3 p.Asp835Val (p.D835V) ( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V) ( ENST00000241453.12 ) |
Sensitivity | true | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 L191F ... | PRPS1 | PRPS1 L191F PRPS1 L191F | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 S103T ... | PRPS1 | PRPS1 S103I PRPS1 S103I | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 S103N ... | PRPS1 | PRPS1 S103I PRPS1 S103I | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 K176N ... | PRPS1 | PRPS1 K176N PRPS1 K176N | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 D183E ... | PRPS1 | PRPS1 D183E PRPS1 D183E | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 A190T ... | PRPS1 | PRPS1 A190V PRPS1 A190V | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 T303S ... | PRPS1 | PRPS1 T303S PRPS1 T303S | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Lentiviral-mediated overexpression of PRPS1 N144S ... | PRPS1 | PRPS1 N144S PRPS1 N144S | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Oncogenic BRAF causes chemoresistance by promoting... | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01920737 | Active, not recruiting | Phase 2 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | August 2013 | August 2024 |
| NCT02085408 | Active, not recruiting | Phase 3 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | February 4, 2011 | October 2024 |
| NCT02112916 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma | October 4, 2014 | September 22, 2024 |
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT03568994 | Active, not recruiting | Early Phase 1 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | July 10, 2018 | October 31, 2025 |
| NCT03962465 | Active, not recruiting | Phase 1 | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL | July 22, 2022 | July 2026 |
| NCT02303821 | Active, not recruiting | Phase 1 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | February 16, 2015 | July 14, 2024 |
| NCT02003222 | Active, not recruiting | Phase 3 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | May 19, 2014 | December 4, 2024 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT03836209 | Active, not recruiting | Phase 2 | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | December 6, 2019 | December 2024 |
| NCT04817241 | Active, not recruiting | Phase 1/Phase 2 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | February 10, 2022 | August 1, 2024 |
| NCT02828358 | Active, not recruiting | Phase 2 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | April 1, 2017 | September 22, 2024 |
| NCT02632708 | Active, not recruiting | Phase 1 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | December 31, 2015 | July 2024 |
| NCT00526305 | Completed | Phase 4 | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | January 2000 | April 2005 |
| NCT00526409 | Completed | Phase 4 | LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia | June 2005 | October 2014 |
| NCT00613457 | Completed | Phase 3 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | September 2000 | July 2006 |
| NCT00703820 | Completed | Phase 3 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | August 4, 2008 | August 14, 2020 |
| NCT00788892 | Completed | Phase 2 | Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | October 2008 | December 2011 |
| NCT00850382 | Completed | Phase 1/Phase 2 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | June 2009 | November 2015 |
| NCT00853008 | Completed | Phase 4 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia | January 2003 | December 2012 |
| NCT00866749 | Completed | Phase 2 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | September 12, 2006 | July 26, 2018 |
| NCT01004497 | Completed | Phase 2 | First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | March 2010 | April 2015 |
| NCT01390337 | Completed | Phase 1 | A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | October 2011 | February 2015 |
| NCT00002925 | Completed | Phase 1/Phase 2 | Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia | February 1997 | June 2010 |
| NCT01463046 | Completed | Phase 1 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | January 2012 | December 2018 |
| NCT01477606 | Completed | Phase 2 | Protocol in Acute Myeloid Leukemia With FLT3-ITD | May 2012 | February 26, 2020 |
| NCT01546038 | Completed | Phase 2 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | June 27, 2012 | March 4, 2019 |
| NCT01773408 | Completed | Phase 1 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | February 2013 | June 2016 |
| NCT01890746 | Completed | Phase 2 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | September 5, 2013 | January 25, 2017 |
| NCT01999413 | Completed | Phase 2 | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients | November 2013 | April 2018 |
| NCT02013648 | Completed | Phase 3 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | July 2014 | February 2024 |
| NCT02036489 | Completed | Phase 4 | Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | January 2008 | December 1, 2019 |
| NCT02038777 | Completed | Phase 1 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | March 25, 2014 | December 28, 2023 |
| NCT02236013 | Completed | Phase 1 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | January 7, 2015 | July 26, 2021 |
| NCT02283177 | Completed | Phase 2 | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | January 2015 | December 2019 |
| NCT02326584 | Completed | Phase 1 | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | December 2014 | April 10, 2018 |
| NCT02393859 | Completed | Phase 3 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | November 10, 2015 | November 21, 2022 |
| NCT02403310 | Completed | Phase 1 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | June 18, 2015 | February 1, 2021 |
| NCT01451515 | Completed | Phase 2 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | May 25, 2012 | May 31, 2022 |
| NCT00005793 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide | July 1999 | November 2006 |
| NCT00049517 | Completed | Phase 3 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | December 19, 2002 | December 2019 |
| NCT00109837 | Completed | Phase 2 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | April 2005 | November 2014 |
| NCT00129168 | Completed | Phase 1/Phase 2 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | August 2005 | March 2008 |
| NCT00130195 | Completed | Phase 2 | Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | September 2002 | May 2008 |
| NCT00198991 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) | April 2003 | June 30, 2013 |
| NCT00199004 | Completed | Phase 4 | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab | April 2004 | March 2009 |
| NCT00199017 | Completed | Phase 4 | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults | April 2004 | |
| NCT00199056 | Completed | Phase 4 | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) | October 1999 | December 2005 |
| NCT00266136 | Completed | Phase 3 | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | June 1999 | October 2012 |
| NCT00494897 | Completed | Phase 4 | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia | June 1996 | December 2007 |
| NCT00526175 | Completed | Phase 4 | LAL-BR/2001: Study Treatment to Low Risk ALL | June 2001 | December 2015 |
| NCT02523976 | Completed | Phase 2 | Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | August 1, 2015 | December 31, 2021 |
| NCT02560025 | Completed | Phase 2 | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | December 2015 | December 2018 |
| NCT02582359 | Completed | Phase 1 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | January 2016 | April 2022 |
| NCT02834390 | Completed | Phase 1 | Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | August 12, 2016 | October 19, 2017 |
| NCT02914977 | Completed | Phase 1 | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia | November 2016 | July 15, 2021 |
| NCT03298984 | Completed | Phase 1 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | September 25, 2017 | March 20, 2020 |
| NCT04562792 | Completed | Phase 2 | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia | May 8, 2020 | June 30, 2022 |
| NCT06313437 | Not yet recruiting | Phase 1 | Revumenib in Combination With 7+3 + Midostaurin in AML | September 2024 | March 2, 2027 |
| NCT06124157 | Not yet recruiting | Phase 3 | A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | July 22, 2024 | December 1, 2030 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT06317662 | Not yet recruiting | Phase 2 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | July 31, 2024 | December 21, 2027 |
| NCT06289673 | Not yet recruiting | Phase 4 | Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | July 2024 | May 2039 |
| NCT04440267 | Not yet recruiting | Phase 2 | Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage | June 20, 2020 | December 20, 2025 |
| NCT05735184 | Recruiting | Phase 1 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML | July 18, 2023 | May 2027 |
| NCT03286634 | Recruiting | Phase 2 | ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | April 18, 2017 | March 31, 2033 |
| NCT06361329 | Recruiting | Phase 3 | Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL | April 2024 | March 31, 2027 |
| NCT03390387 | Recruiting | N/A | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) | November 2015 | November 2025 |
| NCT05959720 | Recruiting | Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | September 5, 2023 | June 2030 | |
| NCT04659616 | Recruiting | Phase 1 | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | January 14, 2021 | February 1, 2026 |
| NCT03709758 | Recruiting | Phase 1 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | October 17, 2018 | June 1, 2025 |
| NCT05939180 | Recruiting | Phase 2/Phase 3 | VA vs DA for Newly Diagnosed Hig-risk AML | April 1, 2024 | October 1, 2027 |
| NCT06262438 | Recruiting | Phase 2 | CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients | February 6, 2024 | June 2032 |
| NCT03897127 | Recruiting | Phase 3 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | September 4, 2019 | March 2024 |
| NCT05886049 | Recruiting | Phase 1 | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | November 10, 2024 | December 31, 2027 |
| NCT04043494 | Recruiting | Phase 3 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | August 23, 2019 | November 22, 2027 |
| NCT04061239 | Recruiting | Phase 2 | Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | August 19, 2019 | September 2026 |
| NCT04174612 | Recruiting | Phase 3 | AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance | April 24, 2020 | August 1, 2025 |
| NCT03643276 | Recruiting | Phase 3 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | July 15, 2018 | July 14, 2028 |
| NCT04801797 | Recruiting | Phase 2 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | May 20, 2021 | January 1, 2026 |
| NCT05832320 | Recruiting | N/A | Optimum Induction Therapy of Low-risk APL | January 1, 2023 | December 31, 2024 |
| NCT05342584 | Recruiting | Phase 1 | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | May 25, 2022 | December 2028 |
| NCT05660473 | Recruiting | Phase 2 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | October 31, 2022 | December 30, 2027 |
| NCT05726110 | Recruiting | Phase 3 | Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | January 29, 2023 | December 31, 2024 |
| NCT03701308 | Suspended | Phase 2/Phase 3 | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | March 28, 2019 | December 1, 2025 |
| NCT02343939 | Terminated | Phase 1/Phase 2 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | July 1, 2015 | February 21, 2019 |
| NCT02954653 | Terminated | Phase 1 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | November 28, 2016 | December 5, 2017 |
| NCT03135028 | Terminated | Phase 1 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | May 19, 2017 | February 26, 2019 |
| NCT02198482 | Terminated | Phase 2 | Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | February 2016 | November 2016 |
| NCT03724084 | Terminated | Phase 1/Phase 2 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | April 10, 2019 | November 14, 2022 |
| NCT03850535 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | March 25, 2019 | September 10, 2020 |
| NCT04326439 | Terminated | Phase 2 | AflacLL1901 (CHOA-AML) | January 24, 2020 | March 15, 2022 |
| NCT04778397 | Terminated | Phase 3 | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | July 1, 2021 | March 25, 2024 |
| NCT02419469 | Terminated | Phase 2 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | November 13, 2015 | June 22, 2017 |
| NCT00180128 | Unknown status | Phase 4 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | January 2000 | November 2012 |
| NCT00651261 | Unknown status | Phase 3 | Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | April 2008 | |
| NCT01953770 | Unknown status | N/A | Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008 | February 2008 | July 2020 |
| NCT02660762 | Unknown status | Phase 2 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | January 2016 | January 2019 |
| NCT00131027 | Unknown status | Phase 3 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | September 2002 | September 2011 |
| NCT02432872 | Unknown status | N/A | Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years | April 2015 | May 2021 |
| NCT02416388 | Unknown status | Phase 2/Phase 3 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | January 2015 | |
| NCT02894645 | Unknown status | Phase 4 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | October 2008 | |
| NCT02776605 | Unknown status | Phase 2 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia | June 2016 | August 2023 |
| NCT03444649 | Withdrawn | Phase 1 | Epacadostat, Idarubicin and Cytarabine (EIC) in AML | September 2018 | October 2019 |
| NCT06210750 | Withdrawn | Phase 2 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | August 9, 2024 | September 22, 2026 |